Table Graph
      published meta-analysis   sensitivity analysis   studies

antiviral and associated therapy in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsBCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.68 [0.22; 2.08] 0.68[0.22; 2.08]BCN PEP-CoV-2-Study 1 (Mitja NEJM), 202010%2,497NAnot evaluable infection (PCR positive symptomatic or not)detailed resultsBCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.86 [0.52; 1.42] 0.86[0.52; 1.42]BCN PEP-CoV-2-Study 1 (Mitja NEJM), 202010%NAnot evaluable serious adverse eventsdetailed resultsBCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.89 [0.44; 1.82] 0.89[0.44; 1.82]BCN PEP-CoV-2-Study 1 (Mitja NEJM), 202010%2,497NAnot evaluable adverse eventsdetailed resultsOut of scaleBCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 20.26 [15.67; 26.20] 20.26[15.67; 26.20]BCN PEP-CoV-2-Study 1 (Mitja NEJM), 202010%2,497NAnot evaluable0.520.01.0relative treatment effectwww.metaEvidence.org2024-05-04 13:22 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons